The clinical effects of Parkinson’s Disease (PD) are visually obvious, but the underlying pathology of PD is still not fully understood. In this slide deck, the course, natural history and prognosis of PD are discussed. Infographics on prodromal PD as well as the stages of PD are presented. Research regarding PD progression, including cognitive impairment and comorbidities, are discussed with regards to identifying related biomarkers.

This slide deck was developed by Shen-Yang Lim, Neurologist and Professor at the University of Malaya, Kuala Lumpur, Malaysia, and Joshua Chin Ern Ooi, Neurologist at Queen Elizabeth Hospital, Kota Kinabalu, Malaysia, in collaboration with Cambridge (a division of Prime, Cambridge, UK).

Index for
slide deck

Course, natural history and prognosis

Course, natural history and prognosis
Course, natural history and prognosis
file_download Download slide in HQ

The course of Parkinson’s disease

The course of Parkinson’s disease
The course of Parkinson’s disease
file_download Download slide in HQ
The progression of Parkinson’s disease
The progression of Parkinson’s disease

The clinical effects of Parkinson’s disease (PD) are often visually obvious, but the underlying pathology of PD is still not fully understood.1,2 PD pathology is thought to spread from brain region to brain region over multiple long-distance relays during long periods of …

file_download Download slide in HQ
Clinical symptoms and time course of Parkinson’s disease progression
Clinical symptoms and time course of Parkinson’s disease progression

The progression of PD is generally slow, taking place over years (often many years).4 While diagnosis tends to occur with the onset of motor symptoms, this can be preceded by a long prodromal phase of 15 years or more.5 This prodromal phase is typically characterised by a…

file_download Download slide in HQ
The effect of genetic subtypes of Parkinson’s disease on disease course
The effect of genetic subtypes of Parkinson’s disease on disease course

Compared with people with sporadic Parkinson’s disease, people with LRRK2-associated Parkinson’s disease tend to experience few cognitive and psychiatric symptoms, with slower disease progression, whereas people with GBA-associated Parkinson’s disease tend to experience a…

file_download Download slide in HQ
Thresholds for the appearance of Parkinson’s disease symptoms
Thresholds for the appearance of Parkinson’s disease symptoms

During Stage 1 of PD, many individuals experience a loss of smell (hyposmia) and/or suffer from constipation.2 In addition, sleep may become disordered or disturbed, accompanied by crying out, punching, or kicking during rapid eye movement (REM) sleep,2,3 and people may e…

file_download Download slide in HQ
The therapeutic benefits of modifying the disease course
The therapeutic benefits of modifying the disease course

While there have been major advances in the management and reduction of PD-related symptoms, there is still no effective way of preventing or slowing the underlying neurodegeneration.2,5 As the disease becomes more extensive during its advanced stages, the ability of drug…

file_download Download slide in HQ
Change in levodopa response over time – ‘wearing-off’
Change in levodopa response over time – ‘wearing-off’

Levodopa is the major symptomatic therapy for PD and is the most common first-line therapy because it provides benefit to virtually all patients.1,3 In the short-term, the effects of levodopa tend to be long-lasting and side effects are tolerable.1 In the longer-term, how…

file_download Download slide in HQ
Definitions of terms used in Parkinson’s disease
Definitions of terms used in Parkinson’s disease

The slide includes some basic definitions of terms used to describe the course of PD.

 

References used on slide:
1.Kalia LV, Lang AE. Parkinson’s disease. Lancet 2015; 386 (9996): 896–912.

2.Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearin…

file_download Download slide in HQ
Drug-induced dyskinesias in Parkinson’s disease
Drug-induced dyskinesias in Parkinson’s disease

Levodopa-induced dyskinesias cover a broad clinical spectrum of different types of involuntary movements, ranging from chorea affecting the limbs, trunk, and head, slow dystonic movements, fixed dystonic postures, or (more rarely) myoclonus or ballism.1,2 Levodopa-induced…

file_download Download slide in HQ
Relationship between levodopa administration and motor fluctuations
Relationship between levodopa administration and motor fluctuations

As the extent of neurodegeneration in the substantia nigra becomes greater, its capacity to produce dopamine diminishes to the point where patients require larger doses of levodopa to maintain normal function.4 Motor complications, such dyskinesia and motor fluctuations, …

file_download Download slide in HQ

Related content

grid_view Slide Deck
Parkinson’s Disease – Non-motor Symptom Complex and Comorbidities

In this slide deck, cognitive disorders, mood disorders, quality of life and the comorbidities of PD are discussed

16.03.2025 Parkinson’s Disease
image Image
Survival after cumulative clinical milestones

As shown in an analysis of the course of PD in five groups of patients who developed the disease at different ages

11.03.2025 Parkinson’s Disease
image Image
Disease modification in PD

There is an unmet need for PD therapies which modify the disease course

11.03.2025 Parkinson’s Disease